Transfection of apoptosis related gene Fas ligand in human hepatocellular carcinoma cells and its significance in apoptosis

Jun Chen, Xian-Shi Su, Yong-Fang Jiang, Guo-Zhong Gong, Yu-Huang Zheng, Gui-Yuan Li

AIM: To evaluate the expression of apoptosis related gene Fas ligand (FasL) in human hepatocellular carcinoma (HCC) cells HepG2 and its significance in apoptosis.

METHODS: Levels of soluble Fas ligand (sFasL) in a group of patients with hepatitis B virus (HBV)-induced chronic hepatitis, HBV-positive liver cirrhosis and HCC were evaluated. In a further study, the recombinant eukaryotic expression plasmid pcDNA3.1hisB-FasL was transfected into HCC cells HepG2 by lipofection, and then soluble FasL was examined in the supernatant of culture cells by ELISA. FasL expression in HepG2 cells was detected by immunochemistry. After being stained by annexin V and propidium iodine, cells were passed through a flow cytometer and examined by a fluorescence microscope and a laser scanning microscope.

RESULTS: The sFasL levels were significantly lower in patients with HCC when compared to the patients with hepatitis or liver cirrhosis. In comparison with untransfected cells, the soluble FasL could be detected in the supernatant of transfected cells. FasL was expressed on the membranes and cytoplasm of transfected cells. The apoptotic cell rate was 36.30% in transfected cells, and was 11.53% in untransfected cells. Moreover, the different stage of apoptotic cells could be distinguished by annexin V and propidium iodine staining.

CONCLUSION: Fas ligand is an apoptotic pathway of HCC cells.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: FasL; HCC; sFasL

INTRODUCTION

Apoptosis is a cellular suicide program that is a regular, non-necrotic form of cell death. Apoptosis in epidermal cell can be regulated by a variety of signals of which the Fas/Fas ligand (Fas/FasL) pathway is one of the best-described signals[1-3]. Fas is a transmembrane receptor in the TNF receptor family[4-6] that transduces an apoptotic signal into cells when cross-linked by FasL. The ligand for Fas is expressed by intraepithelial lymphocytes and lamina propria lymphocytes. Lymphocytes expressing FasL are not dependent on either classical or nonclassical major histocompatibility complex restriction but recognize cells expressing Fas[7]. It has been shown that hepatoma cells could express Fas and FasL. Several lines of evidence suggest that Fas/FasL interactions are important in immune-epithelial communication in the liver[8,9]. Recent researches have shown epithelial cells can be apoptotic by self-secretion or side secretion of Fas and FasL without involvement of immune cells[10-13].

Liver cancer is common in China, and its treatment is difficult. To investigate the mechanism of carcinogenesis of liver cancer would facilitate its treatment.

MATERIALS AND METHODS

sFasL test in patients with liver diseases

Soluble Fas ligand was tested by EIA (MBL, USA) in a group of patients with hepatitis B virus (HBV)-induced chronic hepatitis (12 patients), HBV-positive liver cirrhosis (6 patients) and hepatocellular carcinoma (HCC, 16 patients), six volunteers served as normal controls.

Human FasL expression vector construction

Human FasL was amplified by PCR from pBluescript SK (gift from S Nagata, Osaka Bioscience Institute, Japan) using the following oligonucleotides 5’-GCTCTACAGGAC-TGAGAAGAAG-3’ and 5’-CAACATTCTCGGTGCCTG-3’. PCR products were excised using EcoRI and BamHI and ligated into the mammalian expression vector pCDNA3.1hisB (Invitrogen). The resulting pCDNA3.1hisB-hFasL plasmid was purified using the Qtip500 system (Qiagen). The correct insertion of hFasL was verified by PCR and a sequence analysis system (BioSino, Shanghai, China).
Cell culture and transfection
HepG2 cells (stored in Xiangya cell center, Changsha, China) and HepG2.2.15 cells (gift from South Hospital, the First Military Medical University, Guangzhou, China) were cultured at 37 °C containing 50 mL/L CO\textsubscript{2} in Dulbecco’s modified Eagle’s medium and 10 mL/L fetal calf serum supplemented with penicillin-streptomycin and fungizone (GIBCO, Inc.). All transfections were performed using the lipofection system (GIBCO, Inc.). Then the transfected HepG2 cells were cultured with HepG2.2.15 cells.

Expression of human FasL
Twenty-four and 48 h after, the supernatant and cultured HepG2 cells were harvested, soluble FasL was detected using an EIA human FasL detect kit (MBL, USA). HepG2 cells were stained by S-P using a S-P human FasL detect kit (Maixin Bio, Fuzhou, China).

Examination of apoptosis
Forty-eight hours after the HepG2 and HepG2.2.15 cells were cocultured and stained by annexin V and propidium iodine (purchased from Boehringer Mannheim, Germany) and then examined under a fluorescence microscope or a laser scanning microscope to identify the morphological changes of apoptosis. Stained cells were washed twice with PBS, dispersed, filtered through a 360 mesh nylon net to make single cell suspension. 3×10\textsuperscript{9} cells/L were detected by a flow cytometer (FACSort, B-D Co., USA) fluorescent intensity was detected using exciting light 488 nm and emission light 515 nm. The scatter diagram was drawn according to the fluorescent intensity value of one cell. The apoptotic cell rate was calculated.

RESULTS
sFasL in patients with liver disease
After t-test (SPSS10.0), sFasL in patients with HCC (2.8±0.4 pg/L) was different from that in patients with chronic hepatitis (3.2±0.4 pg/L), liver cirrhosis (3.8±1.1 pg/L) and normal control (3.5±0.7 pg/L) (P<0.05).

Verification of the correct insertion of hFasL
PCR and enzyme cut pCDNA31hisB-hFasL plasmid achieved the expected fragments (Figure 1).

DISCUSSION
Fas/FasL play an important role in HCC. Ito et al.\textsuperscript{[14]} evaluated Fas and Fas ligand expression in HCC patients, and found Fas and Fas ligand had a significant prognostic value for disease-free survival, and could be regarded as a new prognostic marker. Yoshitaka\textsuperscript{[15]} found the labeling index of Fas/FasL was lower in cancerous liver tissue than in adjacent noncancerous region (P<0.01), and tended to decrease in proportion to the malignancy of tumor cells.
Fas/FasL expression was not found in poorly-differentiated cancer cells. Fas(-)/FasL (+), FasL-mRNA (+) HCC cells were seen in one specimen of moderately-differentiated cells, suggesting that Fas/FasL expression was decreased in proportion to the malignancy of tumor cells, and infiltrating CD8+ T lymphocytes played a role in apoptosis in HCC. Also, the apoptosis in HCC could be regulated by the suppression of Fas/FasL expression, or sometimes, by the enhancement of FasL expression. Kupffer cells and LPS/Kupffer cell-conditioned supernatants might induce expression of Fas and Fas ligand in malignant glioma cells. Subsequently a significant proportion of malignant glioma cells became apoptotic, as evidenced by positive staining of annexin V and propidium iodide and an increase in cellular DNA fragmentation, suggesting a novel pathway of Kupffer cells against liver metastases, in which tumor cells were apoptotic via the Fas-Fas ligand system induced by TNF released from Kupffer cells. The suppression of Fas/FasL might have a correlation with HCC occurrence, malignancy and metastases[15-19].

Activated lymphocytes have been shown to release soluble forms of FasL (sFasL), which is capable of inducing apoptosis of Fas positive cells. sFasL is also known to induce activation of nuclear factor κB (NF-κB) and/or IL-8 secretion[20,21]. Thus, sFasL has biological activities, though the presence and possible function of sFasL in the liver have not been clarified yet. The present study, therefore, demonstrated that the amounts of sFasL in serum of patients with hepatocellular cancer had a significant difference compared with chronic viral hepatitis and liver cirrhosis, suggesting that sFasL plays an important role in HCC, and is worthy to further studied.

In our study, soluble FasL was found in supernatant of transfected HepG2 cells and expressed on the membranes and cytoplasm of transfected cells, showing that Fas ligand was successfully transfected into HepG2 cells. The apoptotic rate in transfected HepG2 cells was higher than that in the control.

In conclusion, hepatoma cells become apoptotic via the CD95-CD95 ligand system without the involvement of immune cells. Fas L can induce apoptosis of hepatoma cells.

REFERENCES

1. Cicciocippo R, Di Sabatino A, Parroni R, Muza P, D’Alò S, Ventura T, Pistoia MA, Cifone MG, Corazza GR. Increased enteroocyte apoptosis and Fas-Fas ligand system in celiac disease. Am J Clin Pathol 2001; 115: 494-503
2. Demir G, Ozguroglu M, Sayhan N, Molinas-Mandel N, Demirelli F, Buyukunal E, Tuzuner N, Serdengecti S, Berkerda B. Immunomodulating therapy with rIL-2 and interferon alfa induces in vivo expression of Bel-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study). Anticancer Res 1999; 19: 3517-3520
3. Yoshino O, Matsuno H, Nakamura H, Yudoh K, Aye Y, Sawai T, Uzuki M, Yonehara S, Kimura T. The role of Fas-mediated apoptosis after traumatic spinal cord injury. Spine 2004; 29: 1394-1404
4. Suzuki I, Fink PJ. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J Exp Med 1998; 187: 123-128
5. Spielman J, Lee RK, Podack ER. Perforin/Fas-ligand double deficiency is associated with macrophage expansion and severe pancreatitis. J Immunol 1998; 161: 7063-7070
6. Yang H, Fan Y, Teitelbaum DH. Intraepithelial lymphocyte-derived interferon-γ evokes enterocyte apoptosis with parenteral nutrition in mice. Am J Physiol Gastrointest Liver Physiol 2003; 284: 629-637
7. Boulares AH, Zolotoski AJ, Stoica BA, Cuvillier O, Smulson ME. Acetaminophen induces a caspase-dependent and Bel-15-sensitive apoptosis in human hepatoma cells and lymphocytes. Pharmacol Toxicol 2002; 90: 38-50
8. Li B, Perabekam S, Liu G, Yin M, Song S, Larson A. Experimental and bioinformatics comparison of gene expression between T cells from TIL of liver cancer and T cells from UniGene. J Gastroenterol 2002; 37: 275-282
9. Fink PJ. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J Immunol 1998; 161: 7063-7070
10. Rajashekar G, Loganath A, Roy AC, Mongelli JM. Co-expression of Fas (APO-1, CD95)/Fas ligand by BelWo and NIG choriocarcinoma cell lines. Gynecol Oncol 2003; 91: 101-111
11. Siegel RM, Muppidi J, Roberts M, Porter M, Wu Z. Death receptor signaling and autoimmunity. Immunol Rev 2003; 237: 49-512
12. De Freitas I, Fernandez-Somoza M, Essenfeld-Seker E, Cardier JE. Serum levels of the apoptosis-associated molecules, tumor necrosis Factor-alpha/tumor necrosis factor Type-I receptor and Fas/FasL, in sepsis. Chest 2004; 125: 2238-2246
13. Ok SH, Yin HQ, Lee BH. Role of the Fas/Fas ligand death receptor pathway in ginseng saponin metabolite-induced apoptosis in HepG2 cells. Arch Pharm Res 2007; 30: 402-406
14. Ito Y, Monden M, Takeda T, Eguchi H, Umeshiba K, Naganoto, Nakamori S, Dono K, Sakon M, Nakamura M, Tsujimoto M, Nakahara M, Nakao K, Yokotsuka Y, Matsuzaka N. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer 2004; 82: 1211-1217
15. Fukushima M, Takahashi K, Furuta K, Tagaya T, Ishikawa T, Wada K, Pomoto Y, Koji T, Kikumura S. Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC). J Gastroenterol 2001; 36: 681-688
16. Lau WY, Chen GG, Lai PB, Chun YS, Leung BC, Chak CE, Lee JP, Chui AK. Induction of Fas and Fas ligand expression on malignant glioma cells by Kupffer cells, a potential pathway of antiliver metastases. J Surg Res 2001; 101: 44-51
17. Nakamoto Y, Kaneko S, Fan H, Momoi T, Tsutsui H, Nakanishi K, Kobayashi K, Suda T. Prevention of hepatocellular carcinoma. Br J Cancer 2004; 82: 1105-1111
18. Mauz-Korholz C, Banning U, Korholz D. Regulation of interleukin-2 induced soluble Fas ligand release from human peripheral blood mononuclear cells. Immunol Invest 2004; 33: 251-260
19. Kaur H, Jaso-Friedmann L, Evans DL. Single base oligodeoxyguanosine upregulates Fas ligand release by nonspecific cytotoxic cells. Dev Comp Immunol 2004; 28: 571-579
20. Nakamoto N, Mukea H, Fujii T, Kakugawa T, Kaida H, Kadota J, Kohno S. Soluble form of Fas and Fas ligand in serum and bronchoalveolar lavage fluid of individuals infected with human T-lymphotropic virus type 1. Respir Med 2004; 98: 213-219
21. Sugita S, Taguchi C, Takase H, Sagawa K, Sueda J, Fukushima H, Kikita N, Watanabe T, Itoh K, Mochizuki M. Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis. Br J Ophthalmol 2000; 12: 1130-1134